Metropolis Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on November 04, 2025, declared Interim Dividend of Rs. 4 per equity share.
METROPOLIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Metropolis Healthcare announced its Q2 and H1 FY26 results (ended September 30, 2025) along with an interim dividend of Rs. 4 per share (face value Rs. 2). Consolidated revenue grew strongly at about 23% year-on-year for both Q2 (Rs. 429.2 cr vs Rs. 349.8 cr) and H1 (Rs. 815.3 cr vs Rs. 663.1 cr), boosted by recent acquisitions. Consolidated profit after tax rose around 13% in Q2 to Rs. 52.9 cr and about 16% in H1 to Rs. 98.1 cr. On a standalone basis, Q2 PAT jumped nearly 31% YoY to Rs. 46.6 cr, while revenue grew about 10%. The Board also noted three business acquisitions completed during the period (DAPIC, Scientific Metropolis, and Dr. Patil's Ambika Pathology) and an update on the long-running income tax matter, where the demand has been reduced from Rs. 73 cr to Rs. 38.8 cr following favorable appellate orders. The statutory auditors (BSR & Co. LLP) issued an unmodified limited review report on the results.
The strong consolidated revenue growth and an interim dividend payout are positive signals for shareholders, though most of the revenue boost came from acquisitions rather than organic growth. Investors should note the increased debt-like exposure through OCDs to fund acquisitions and the ongoing income tax litigation, even though recent appellate outcomes have been favorable.